NCT04627584Unknown2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients With Mild or Moderate COVID-19
适应症
干预措施
试验速览
- 阶段
- 2 期
- 入组人数
- 150
- 试验地点
- 1
- 主要终点
- SARS-CoV-2 viral load
研究概览
简要总结
This study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the clinical efficacy and safety of MW33 injection in patients with mild or moderate COVID-19, and to evaluate its pharmacokinetic profile and immunogenicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with mild or moderate COVID-19 (as per the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial, 8th edition), China, or Clinical Management of COVID-19, WHO);
- •Has at least one COVID-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 7 days prior to randomization;
- •The SARS-CoV-2 nasopharyngeal nucleic acid is tested to be positive (RT-PCR), IgM (-)/IgG (-) or IgM (+)/IgG (-) within 3 days before randomization;
- •Male or female subjects aged 18 to 80 years (including 18 and 80 years);
- •Subjects do not have a pregnancy plan, voluntarily take effective contraceptive measures during the screening period and the next 6 months, and have no sperm and egg donation plans, and voluntarily take non-pharmaceutical contraception measures during the trial period;
- •Subjects voluntarily sign the informed consent form (ICF) based on sufficient knowledge of the nature, purpose, and procedures of the study, and shall be willing to comply with the study regulations.
排除标准
- •A subject who was diagnosed with severe or critical COVID-19 (as per the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial, 8th edition), China, or Clinical Management of COVID-19, WHO);
- •Abnormal important organ function indicators, which meet the following conditions:
- •① Liver function: serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) > 5.0 × upper limit of normal (ULN);
- •② Renal function: patients treated with dialysis or eGFR< 60 mL/min.
- •③ Cardiac function: patients with results of 12-lead ECG suggesting conduction block or acute myocardial infarction requiring urgent management;
- •Suspected or diagnosed with serious bacterial, fungal, viral, or other infection (except SARS-CoV-2 infection). In the opinion of the investigator, the conditions will prevent a subject from completing the study or impact interpretation of the study results;
- •Currently suffering from serious systemic diseases or mental disorders, and ineligible to participate in the study judged by the investigator;
- •A history of severe trauma, fracture, or surgery within 4 weeks prior to screening, or possibility of requiring a major surgery during the study;
- •Participated in clinical trials of SARS-CoV-2 vaccine or SARS-CoV-2 monoclonal antibody;
- •Received or being receiving the convalescent plasma from patients recovered from COVID-19;
- •Prior or current use of antiviral drugs for treatment of COVID-19, including Remdesivir, Tocilizumab, Interferon, Ribavirin, Abidol, Lopinavir, and Ritonavir, etc.
- •Currently enrolled into clinical studies with other drugs or devices; the time to start of this study from the end of previous participation in other drug clinical studies is less than 30 days, or within 5 half-lives, or within the biological effect period of the drug (whichever is longer);
- •Those who are known to be allergic to any component of the investigational product; or those who have a history of allergies and judged by the investigator to be ineligible for enrollment;
- •Females who are pregnant or lactating;
- •Any conditions that are not suitable for enrollment judged by the investigator.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: MW33 injection placebo (Combination Product)
MW33 injection-1200mg
Active Comparator
干预措施: MW33 injection (Combination Product)
MW33 injection-2400mg
Active Comparator
干预措施: MW33 injection (Combination Product)
结局指标
主要结局
SARS-CoV-2 viral load
时间窗: 7 Days
Change in time-weighted SARS-CoV-2 viral load in nasopharyngeal swabs from baseline to day 7
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)MelanomaNCT01009177Actelion80
招募中
1 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by VirusesSevere Viral Pneumonia(Not Include COVID-19)NCT06693362Ruijin Hospital60
已完成
2 期
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer PatientsAlzheimer DiseaseNCT03184467GemVax & Kael96
Unknown
4 期
Efficacy and Safety of Yuxuebi Tablet in Treating Night Pain of Ankylosing Spondylitis (AS).Ankylosing SpondylitisNCT04934059China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.60
Unknown
4 期
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase InjectionHemoptysisNCT03270735Lee's Pharmaceutical Limited100